Kineta Free Cash Flow 2014-2024 | KANT
Kineta free cash flow from 2014 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Kineta Annual Free Cash Flow |
| 2023 |
-15.88 |
| 2022 |
-19.04 |
| 2021 |
-17.85 |
| 2020 |
-18.17 |
| 2019 |
-27.85 |
| 2018 |
-59.26 |
| 2017 |
-52.51 |
| 2016 |
-42.14 |
| 2015 |
-19.68 |
| 2014 |
-8.83 |
| 2013 |
-12.96 |
| Kineta Quarterly Free Cash Flow |
| 2024-06-30 |
-5.23 |
| 2024-03-31 |
-4.01 |
| 2023-12-31 |
-15.88 |
| 2023-09-30 |
-11.80 |
| 2023-06-30 |
-11.60 |
| 2023-03-31 |
-4.66 |
| 2022-12-31 |
-19.04 |
| 2022-09-30 |
-11.55 |
| 2022-06-30 |
-8.47 |
| 2022-03-31 |
-5.39 |
| 2021-12-31 |
-17.85 |
| 2021-09-30 |
-40.29 |
| 2021-06-30 |
-31.99 |
| 2021-03-31 |
-22.29 |
| 2020-12-31 |
-18.17 |
| 2020-09-30 |
-6.54 |
| 2020-06-30 |
-14.46 |
| 2020-03-31 |
-8.45 |
| 2019-12-31 |
-27.85 |
| 2019-09-30 |
-41.56 |
| 2019-06-30 |
-31.06 |
| 2019-03-31 |
-13.44 |
| 2018-12-31 |
-59.26 |
| 2018-09-30 |
-39.91 |
| 2018-06-30 |
-25.27 |
| 2018-03-31 |
-12.03 |
| 2017-12-31 |
-52.51 |
| 2017-09-30 |
-40.67 |
| 2017-06-30 |
-27.80 |
| 2017-03-31 |
-15.36 |
| 2016-12-31 |
-42.14 |
| 2016-09-30 |
-27.84 |
| 2016-06-30 |
-15.23 |
| 2016-03-31 |
-8.42 |
| 2015-12-31 |
-19.67 |
| 2015-09-30 |
-13.12 |
| 2015-06-30 |
-6.61 |
| 2015-03-31 |
-4.54 |
| 2014-12-31 |
|
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
